Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 270-275

  Mohamed, Mohamed Eslam F ^a   Frye, Reginald F ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; BILOBALIDE; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GLUCURONIDE; KAEMPFEROL; MYCOPHENOLIC ACID; QUERCETIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; INTESTINE; LIVER; LIVER MICROSOME; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GINKGO BILOBA; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; HUMANS; HYDROLYSIS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KAEMPFEROLS; KINETICS; LIVER; MICROSOMES; MYCOPHENOLIC ACID; PLANT EXTRACTS; QUERCETIN;

GINKGO BILOBA;

EID: 76149099869     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030080     Document Type: Article

References (37)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Auton Control 19:716-723.
2. Allison AC and Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80:S181-S190.
3. Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, and Wallace RB (2007) Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc 82:561-566.
4. Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, Kamphues J, and Wolffram S (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138:1417-1420.
5. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
6. Chan PC, Xia Q, and Fu PP (2007) Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:211-244.
7. Chang JH, Yoo P, Lee T, Klopf W, and Takao D (2009) The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe. Mol Pharm 6:1216-1227.
8. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Wiley-Interscience, Hoboken, NJ.
9. D'Andrea V, Pérez LM, and Sánchez Pozzi EJ (2005) Inhibition of rat liver UDPglucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. Life Sci 77: 683-692.
10. De Smet PA (2005) Herbal medicine in Europe-relaxing regulatory standards. N Engl J Med 352:1176-1178.
11. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, and Walle T (1996) Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos 24:232-237.
12. Gardiner P, Phillips R, and Shaughnessy AF (2008) Herbal and dietary supplement-drug interactions in patients with chronic illnesses. Am Fam Physician 77:73-78.
13. Ghazali RA and Waring RH (1999) The effects of flavonoids on human phenolsulphotransferases: potential in drug metabolism and chemoprevention. Life Sci 65:1625-1632.
14. Heatwole C and Ciafaloni E (2008) Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat 4:1203-1209.
15. Hellum BH, Hu Z, and Nilsen OG (2007) The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100:23-30.
16. Hertog MG, Hollman PC, Katan MB, and Kromhout D (1993) Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20:21-29.
17. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, and Katan MB (1995) Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62:1276-1282.
18. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, and Zhou S (2005) Herb-drug interactions: a literature review. Drugs 65:1239-1282.
19. Izzo AA and Ernst E (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777-1798.
20. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
21. Kupiec T and Raj V (2005) Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 29:755-758.
22. Lamson DW and Brignall MS (2000) Antioxidants and cancer, part 3: quercetin. Altern Med Rev 5:196-208.
23. Li L, Stanton JD, Tolson AH, Luo Y, and Wang H (2009) Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptormediated pathways. Pharm Res 26:872-882.
24. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, and Ritter JK (2005) An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33:1513-1520.
25. Mohamed MF, Harvey SS, and Frye RF (2008) Determination of mycophenolic acid glucuronide in microsomal incubations using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 870:251-254.
26. NBJ (2008) NBJ's supplement business report. Nutr Bus J Jan 15.
27. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, and van Leeuwen PA (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74:418-425.
28. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDPglucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
29. Ouzzine M, Barré L, Netter P, Magdalou J, and Fournel-Gigleux S (2003) The human UDPglucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metab Rev 35: 287-303.
30. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
31. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
32. Sampson L, Rimm E, Hollman PC, de Vries JH, and Katan MB (2002) Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 102:1414-1420.
33. Scalbert A and Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S-2085S.
34. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034.
35. Staatz CE and Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13-58.
36. Strandell J, Neil A, and Carlin G (2004) An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 11:98-104.
37. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.